Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hung Out As Axovant Rebuilds Its Pipeline, Expands Focus Beyond Dementia

Executive Summary

CEO Hung resigns after less than a year; he and several others leave behind a dementia-focused specialty pharma that will return to its entrepreneurial roots to build a broader neuroscience pipeline. Parent company Roivant turns to a less conventional choice, Parvan Cheruvu, to take the helm.

Advertisement

Related Content

Roivant's New Respiratory-Focused Vant Adds Chronic Cough Candidate To The Portfolio
After Bad Data Comes Layoffs – Will The Next Job Cuts Be At Anthera?
Appointments: Changes At Axovant Sciences, Immunocore, Sangamo Therapeutics, Circassia, MaxCyte and CANbridge Life Sciences
Finance Watch: Roivant Raises $1.1bn, Relying On Private Equity To Fund New Companies
Full Circle: David Hung Looks Forward To Axovant's Alzheimer's Data, Reflects On Medivation

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100386

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel